ArticleDrug delivery and translational research2025
In vitro skin permeation of mitragynine: Optimisation of antioxidants for enhanced drug stability and formulation performance.
Article in Drug delivery and translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Multifunctional Bacterial Cellulose Films Incorporating Kratom (Nanomaterials (Basel, Switzerland) · 2026Article
- Transdermal delivery and anti-inflammatory efficacy of Mitragyna speciosa extract transdermal patch for local inflammation management: in vitro, ex vivo, and in vivo investigations.Drug delivery and translational research · 2026Article
- Transdermal delivery and anti-inflammatory efficacy of Mitragyna speciosa extract transdermal patch for local inflammation management: in vitro, ex vivo, and in vivo investigations.Drug delivery and translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The opioid-like characteristics of mitragynine with biased μ-opioid receptor activation are attractive for pain and addiction therapy due to less addictive issue. Our previous work has shown the potential of delivering mitragynine through the skin but drug degradation hindered a reliable understanding of its permeation behaviour. This study aims to optimise the use of antioxidants in both the receptor medium and formulations for in vitro permeation studies of mitragynine (5%w/v) using single solvent systems. The optimised receptor medium with 0.01%w/v of ascorbic acid in phosphate buffer saline was chosen due to a high mitragynine recovery that also allowed the detection of a higher mitragynine amount permeated. Dimethyl sulphoxide and Transcutol
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.